GET DAILY SIGNALSAnnexon Biosciences (ANNX) Q3 2025 Results Show Wider Loss but Extended Cash Runway
Key Takeaways
- Annexon reported a third-quarter 2025 net loss of $54.9 million, or $0.37 per share, compared with a loss of $0.25 per share in the prior-year period.
- The result came in slightly below consensus estimates of a $0.34 per-share loss, according to aggregated analyst data.
- Research and development (R&D) expenses rose to $49.7 million from $30.1 million a year earlier, reflecting investment in late-stage clinical programs.
- The company ended the quarter with $188.7 million in cash, cash equivalents, and short-term investments, extending its operating runway into late first quarter 2027.
- Annexon remains pre-revenue, with the next major catalyst — topline Phase 3 ARCHER II data — expected in the second half of 2026.
- For more detail on ANNX's Major News, Today's Price Move, Price Targets, and Forecasts, visit the dedicated ticker pages.
- To discover AI-driven trading strategies, explore Trending AI Robots.
Why These Results Matter for a Pre-Revenue Biotech
Annexon Biosciences is a clinical-stage biopharmaceutical company advancing therapies for classical complement-mediated neuroinflammatory diseases affecting the body, brain, and eye. Because the company is pre-revenue, its quarterly results are less about top-line sales and more about cash management, spending discipline, and clinical progress. The third-quarter 2025 report matters because it shows how efficiently Annexon is deploying capital across its lead programs — ANX005 (vonaprument, also referred to as tanruprubart) for Guillain-Barré syndrome (GBS), ANX007 for geographic atrophy (GA, an advanced form of age-related macular degeneration), and ANX1502 for autoimmune conditions. An extended cash runway reduces near-term financing risk while investors await pivotal data readouts. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Breaking Down the Reported Figures
Annexon reported a net loss of $54.9 million, or $0.37 per share, for the third quarter ended September 30, 2025. That compares with a net loss of $34.8 million, or $0.25 per share, in the same period a year ago. The per-share loss was slightly wider than the $0.34 consensus estimate tracked by financial data providers, representing a modest miss.
R&D expenses climbed to $49.7 million from $30.1 million in the prior-year quarter, driven primarily by the advancement of the Phase 3 ARCHER II trial of vonaprument in geographic atrophy and investments toward completing global regulatory filings for tanruprubart in GBS. General and administrative (G&A) expenses declined to $7.3 million from $9.3 million, reflecting corporate efficiencies and disciplined resource prioritization.
On the balance sheet, cash, cash equivalents, and short-term investments totaled $188.7 million as of September 30, 2025. Management said the company expects this to fund operations and anticipated milestones into late first quarter 2027.
Market Reaction and Investor Sentiment
Annexon shares are primarily driven by clinical catalysts and cash-position signals rather than the headline EPS figure. In the third quarter, the slightly wider-than-expected loss was offset by the extended cash runway, which addresses a key concern for pre-revenue biotech investors: dilution risk. The announcement that funding now stretches into late first quarter 2027 reduces the urgency of a near-term capital raise, which can be viewed favorably even as losses expand in absolute terms. Investor sentiment remains anchored to the timing and quality of upcoming data readouts, particularly the Phase 3 ARCHER II topline results and the ANX1502 proof-of-concept (POC) study in cold agglutinin disease (CAD).
Forward Outlook and Key Factors to Monitor
The most important catalyst on Annexon's calendar is the topline result from the Phase 3 ARCHER II trial of vonaprument in geographic atrophy, expected in the second half of 2026. That readout will be central to the investment thesis, as it tests whether the therapy can meaningfully slow vision loss in GA patients. Investors should also watch for completion of the ANX1502 proof-of-concept study in CAD, with a program update anticipated in 2026.
On the financial side, the extended runway into late first quarter 2027 provides a clearer window for executing these milestones, but R&D spending is likely to remain elevated as pivotal trials and regulatory filings progress. Any changes to guidance around the timing of clinical data, filing submissions, or the cash runway should be monitored closely. From what I see, broader sentiment toward clinical-stage biotech and the competitive landscape in complement-mediated diseases could influence how the market interprets upcoming results.
Using AI Tools in My Research Process
In my view, tools like Tickeron’s AI Screener help me quickly compare clinical-stage names such as ANNX against peers on fundamentals and technical signals. I find it useful for spotting how biotech stocks are positioned ahead of data readouts without manually sifting through dozens of screens. This kind of filtering supports a more disciplined approach when building a watchlist around catalysts like the upcoming Phase 3 results.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ANNX in -2.89% downward trend, falling for three consecutive days on October 26, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ANNX declined for three days, in 286 of 321 cases, the price declined further within the following month. The odds of a continued downward trend are 89%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 54 cases where ANNX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for ANNX entered a downward trend on October 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ANNX's RSI Indicator exited the oversold zone, 34 of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Momentum Indicator moved above the 0 level on November 03, 2026. You may want to consider a long position or call options on ANNX as a result. In 67 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for ANNX just turned positive on October 19, 2026. Looking at past instances where ANNX's MACD turned positive, the stock continued to rise in 35 of 45 cases over the following month. The odds of a continued upward trend are 78%.
ANNX moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +9.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where ANNX advanced for three days, in 224 of 262 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
ANNX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. ANNX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 59 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.279) is normal, around the industry mean (3.498). P/E Ratio (-3.717) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANNX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain
Industry Biotechnology
Advertisement